Chemed stock performance snapshot after recent price moves

Chemed (CHE) has drawn fresh attention after recent price moves, with the stock last closing at US$520.27. That level reflects mixed short term returns and a stronger picture over the past 3 months.

Over the past year Chemed has delivered a 15.74% total shareholder return. The recent 1 day share price move down 5.16% to US$520.27 contrasts with a 22.01% 90 day share price return, suggesting momentum has cooled slightly after a strong run.

Scan for other healthcare stocks showing similar momentum and financial resilience with the hand picked list of solid balance sheet and fundamentals (50 results)

After a strong 90 day run and a sharp single day pullback, Chemed now sits in a grey zone for timing. Does that recent drop offer a fair entry, or does the valuation still call for patience before buying more?

Most Popular Narrative: 11.8% Undervalued

The most widely followed narrative on Chemed pegs fair value at $590, compared with the last close at $520.27. That gap frames a story built around hospice mix shifts, regulatory resolutions, and how the Roto-Rooter segment is managed.

VITAS is repositioning its admission mix away from an unusually high share of short-stay, hospital based patients toward a more balanced pattern that historically supports higher average daily census, which could feed through to steadier revenue growth and stronger EBITDA margins over time.

Want to see what underpins that fair value for Chemed? The narrative leans heavily on how revenue, margins and long term earnings power are expected to reshape from here. The key assumptions are all laid out, but the real story is how they fit together.

Result: Fair Value of $590 (UNDERVALUED)

However, Chemed’s story still carries real risks, including potential Medicare rule changes, as well as pressure on Roto Rooter’s digital lead costs and water restoration billing.

Next Steps

Given the mix of opportunities and concerns around Chemed, it may be helpful to move quickly and review the full picture yourself. To consider the potential benefits alongside the potential risks in one place, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Chemed?

If Chemed has you thinking more broadly about opportunities, use a few minutes today to scan for other stocks that match the kind of profile you want.

• Target reliable cash generators by reviewing companies with strong yields and defensible payouts through the 12 dividend fortresses.
• Hunt for quality at a measured price by checking businesses that combine solid fundamentals with appealing valuations using the 20 high quality undiscovered gems.
• Prioritise resilience first by focusing on companies that pair sturdy balance sheets with dependable fundamentals through the list of solid balance sheet and fundamentals (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.